Investments

Co-Investment
Held / Exited
  • Norstella-logo
    Co-Investment

    Norstella

    United-Kingdom

    Healthcare & life science
    Healthcare & life science

    Norstella is a leading provider of pharma data products including clinical trial data solutions and expert advisory services through advanced technologies such as real-world data, machine learning, and predictive analytics.

  • Logo renta
    Co-Investment

    Renta

    Finland

    Industrials
    Industrials

    Founded in 2015, Renta is a full service equipment rental company offering construction machines & equipment, modular on-site facilities, scaffolding and weather protection, as well as related on-site services. Renta focuses on small & mid-sized enterprises customers.

  • WS Audiology logo
    Co-Investment

    WS Audiology

    Denmark

    Healthcare & life science
    Healthcare & life science

    WS Audiology (WSA) is the result of the merger of Sivantos and Widex in 2019 and is now a global hearing aids player. The company develops, manufactures and sells hearing aids products through a global multi-channel strategy and owns a multi-brand portfolio (Signia, Widex, Rexton, Audio Services, etc.).

  • logo palex bon.jpg
    Co-Investment

    Palex

    Spain

    Healthcare & life science
    Healthcare & life science

    Founded in 1955, Palex is a Southern Europe independent distributor of medical devices to public and private hospitals. With a wide product portfolio, Palex covers different therapeutic areas thanks to partnerships with OEMs mostly through exclusive contracts. It operates across Spain, Portugal and Italy.

The Ardian team brought a deep sector knowledge, which I think allowed them not only to do a terrific job in that due diligence period, but also meant they could work very efficiently within our deal time frame.

Doug Brody KKR Capital Market

Ardian and Arsenal both want our investments to benefit society and by working together in this case we’ve reduced the time it takes to set up a clinical trial by many months, which means new drugs come to market as quickly and safely as possible.

Steve McLean Partner of Arsenal Capital

During the due diligence phase, we identified Ardian as a future shareholder capable of making a significant contribution to Emera's development. As soon as the transaction closed, we were able to define and launch value-creating initiatives with Naxicap and Ardian, particularly in terms of group structuring, external growth, digital transformation and real estate strategy, in France but also in Spain and other European countries.

Eric Baugas CEO of EMERA